Abstract
Background Low-grade serous ovarian carcinoma (LGSOC) is a distinct, under-investigated and relatively chemotherapy-resistant ovarian cancer type. Understanding the molecular landscape is crucial to maximise the impact of molecularly-targeted therapy.
Methods Whole exome sequencing and copy number data were integrated with histopathological patterns, ER/PR expression, and detailed clinical annotation, including survival, in a carefully curated LGSOC cohort.
Results 63 tumours were analysed in the largest comprehensive genomic LGSOC study to date. Three genomic subgroups were identified: canonical MAPK mutant (cMAPKm: 52%, KRAS/BRAF/NRAS), MAPK-associated mutation (27%, 14 MAPK-associated genes) and MAPK wild-type (MAPKwt: 21%). MAPKwt patients were younger at diagnosis (median 47 versus 62 years in the cMAPKm subgroup) and demonstrated shorter survival [multivariable HR (mHR) 4.17]. The inferior survival in the MAPKwt subgroup was due to shorter post-relapse survival (mHR 5.22) rather than shorter time to first progression (mHR 1.15). Patients in the MAPK-associated mutation subgroup had similar survival to cMAPKm cases. The cMAPKm subgroup more frequently demonstrated macropapillary invasion. Desmoplasia and micropapillary invasion were independently associated with poor survival. NOTCH pathway activation occurred independently of MAPK subgroup.
Conclusions LGSOC comprises multiple genomic subgroups with distinct clinical, molecular and histopathological features. True MAPKwt cases represent around a fifth of patients: they are younger but have poorer survival. New therapeutic strategies with activity in this subgroup are urgently required. NOTCH inhibitors represent a therapeutic strategy worthy of exploration.
Competing Interest Statement
RLH: consultancy fees from GlaxoSmithKline. FN: non-personal interests in AstraZeneca and Tesaro. CG: research funding from Roche, AstraZeneca, Novartis, Aprea, Nucana, GSK, Tesaro, BerGen Bio, Medannexin, Verastem; honoraria/consultancy fees Roche, AstraZeneca, MSD, GSK, Tesaro, Nucana, Clovis, Foundation One, Chugai, Sierra Oncology, Cor2Ed and Takeda; named on issued/pending patents related to predicting treatment response in ovarian cancer outside the scope of the work described here. All other authors declare no conflicts of interest.
Funding Statement
RLH was supported by Target Ovarian Cancer. This work was funded in part by a HANARTH Foundation grant. We extend our thanks to The Nicola Murray Foundation for their generous support of The Nicola Murray Centre for Ovarian Cancer Research. JT and CB were supported by core funding from the CRUK Edinburgh Centre. AMM was supported by core funding awarded to the MRC Human Genetics Unit.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Lothian Human Annotated Bioresource (reference 15/ES/0094-SR925), NKI-AVL Translational Research Board (reference CFMPB284), and University of Amsterdam AMC Biobank Assessment Committee (reference 2016_070#A201641). All participants provided written informed consent or had consent waived by the ethics committee due to the retrospective nature of the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The genomic data presented in this manuscript are being made available via deposition in the European Genome-Phenome Archive. We are happy to provide data to researchers upon reasonable request and in compliance with our research ethics framework.
